| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Ludwig Institute Clinical Trial Center and
Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032;
Institute for Cell Biology, Department of Immunology, University of Tubingen, Tubingen, Germany;
Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY 10021;
¶ Department of Pathology, Weill Medical College of Cornell University, New York, NY 10021;
|| Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland; and
# Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland
Accumulating evidence supports the requirement for both tumor-specific CD8+ and CD4+ T cell responses for efficient tumor rejection to occur. Because of its expression in different tumor types, the cancer/testis Ag encoded by the synovial sarcoma X breakpoint 2 (SSX-2) gene is among the most relevant candidates for the development of generic cancer vaccines. The immunogenicity of SSX-2 has been previously corroborated by detection of specific humoral and CD8+ T cell responses in cancer patients. In this study we report identification of the first CD4+ T cell epitope encoded by SSX-2. The identified epitope mapped to the 19–34 region of the protein and was recognized by CD4+ T cells from an Ag-expressing melanoma patient in association with HLA-DPB1*0101. The absence of detectable response in healthy donors and other patients suggests that SSX-2-specific CD4+ T cells in the responder patient had been previously expanded in vivo in response to the autologous tumor. The epitope did not appear to be presented on the surface of tumor cells at levels sufficient to allow direct recognition. In contrast, it was efficiently presented by autologous dendritic cells, supporting the concept that processing by professional APC is the main pathway through which the CD4+ T cell immunoresponse to tumor Ags occurs in vivo.
This article has been cited by other articles:
|
|
 |
|
  D. Valmori, F. Qian, M. Ayyoub, C. Renner, A. Merlo, S. Gjnatic, E. Stockert, D. Driscoll, S. Lele, L. J. Old, et al. Expression of Synovial Sarcoma X (SSX) Antigens in Epithelial Ovarian Cancer and Identification of SSX-4 Epitopes Recognized by CD4+ T Cells Clin. Cancer Res., January 15, 2006; 12(2): 398 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Neumann, C. Wagner, K.-D. Preuss, B. Kubuschok, C. Schormann, S. Stevanovic, and M. Pfreundschuh Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells Blood, November 1, 2005; 106(9): 3105 - 3113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ayyoub, A. Merlo, C. S. Hesdorffer, D. Rimoldi, D. Speiser, J.-C. Cerottini, Y.-T. Chen, L. J. Old, S. Stevanovic, and D. Valmori CD4+ T Cell Responses to SSX-4 in Melanoma Patients J. Immunol., April 15, 2005; 174(8): 5092 - 5099. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
